ICON plc is a global clinical research organization founded in Dublin in 1990. It provides clinical development and commercialization services across many therapeutic areas and is publicly listed on Nasdaq as ICLR.
The global drug discovery services market is valued at $22.04 billion in 2025 and is forecast to reach $75.13 billion by 2034, growing at a 14.6% CAGR from 2026-2034, driven by rising industry demand and technological advancements.
The clinical trials industry is expected to grow from $61.93 billion in 2025 to $99.25 billion by 2033 at a 6.07% CAGR, driven by demand for innovative therapies and chronic disease prevalence. Clinical trials management systems are projected to reach $9.0 billion by 2035.
Trellus Health announced a six-month extension of its contract with Johnson & Johnson to provide the Trellus Elevate platform for inflammatory bowel disease patients, driven by strong engagement and satisfaction metrics achieved during the pilot phase.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07514338 |
Open Label Extension to Assess Long Term Safety and Efficacy of KL1333 in Patients With Primary Mitochondrial Disease |
NOT_YET_RECRUITING | PHASE2 |
| NCT07430306 |
A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus |
RECRUITING | PHASE3 |
| NCT07205666 |
The Eplontersen Pregnancy and Lactation Outcomes Study |
RECRUITING | |
| NCT07199569 |
Comparability Trial of the MVA-BN Vaccine Manufactured in Different Production Cells |
ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT07076030 |
Pharmacokinetics of Petrelintide Following Administration to Participants With Impaired Renal Function |
COMPLETED | PHASE1 |
| NCT07059000 |
A Study Investigating Intravenous Human Normal Immunoglobulin 10% in Adults With Chronic Immune Thrombocytopenia (ITP) |
RECRUITING | PHASE3 |
| NCT06941025 |
Maternal and Postnatal Outcomes Study (MOS): A Global Observational Registry Assessing the Safety of Elfabrio® in Women With Fabry Disease and Their Infants During Pregnancy and Breastfeeding |
RECRUITING | |
| NCT06716606 |
A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Interstitial Lung Disease (ILD) Associated With Systemic Sclerosis (SSc) and Other Connective Tissue Diseases (CTD) (BLISSconneCTD-OLE) |
RECRUITING | PHASE3 |
| NCT06564974 |
Registry Study to Observe Long-term Safety of Vamorolone (AGAMREE®) in Patients With Duchenne Muscular Dystrophy-SUMMIT |
RECRUITING | |
| NCT06560151 |
Assess Safety and Immunogenicity of A/H5 Inactivated Monovalent Influenza Vaccines at Different Antigen Dose Levels Adjuvanted With AS03 or MF59 |
COMPLETED | PHASE2 |
